signature=db1329ad01be7a16eb46c986db4f43ee,current status of oncothermia therapy for lung cancer

Korean J Thorac Cardiovasc Surg 2014;47:77-93

□ Review □

http://www.doczj.com/doc/1fc1a1b5af1ffc4fff47acdd.html/10.5090/kjtcs.2014.47.2.77

ISSN: 2233-601X (Print) ISSN: 2093-6516 (Online)

Department of Biotechnics, St. Istvan University, Godollo, Hungary

Received: February 28, 2014, Revised: March 24, 2014, Accepted: March 28, 2014

Corresponding author:Andras Szasz, Department of Biotechnics, St. Istvan University, Godollo, Ibolya u. 2. 2071 Paty, Hungary

(Tel) 36 (23) 555 510 (Fax) 36 (23) 555 515 (E-mail) Szasz.Andras@gek.szie.hu

C The Korean Society for Thoracic and Cardiovascular Surgery. 2014. All right reserved.

CC This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://www.doczj.com/doc/1fc1a1b5af1ffc4fff47acdd.html/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Current Status of Oncothermia Therapy for Lung Cancer

Andras Szasz, Ph.D.

INTRODUCTION

Cancer morbidity worldwide is growing. However in the United States, the overall morbidity slightly decreased in 2013, (by ＞0.6%/yr in men, but it was stable in women), while the mortality rates decreased by 1.8%/yr in men and by 1.5%/yr in women [1]. The lung was the site of the highest cancer mortality in both the sexes (28% and 26% in men and women, respectively, while the second highest mortality rates, prostate cancer in men and breast cancer in women (10% and 14%, respectively), were nearly half those of the lung cancer rates [1]. While the disease, when recognized in its localized state, has good five-year survival (52%), the regional or far distant stages have survival rates of only 25% and 4%, respectively. However, at the first diagnosis, 56% of cases al-ready show distant metastatic lesions, while only 22% are re-

gional and 15% are local only [2]. This is why the overall survival data shows a sad picture: relative survival rates (male/female) are 29.4%/33%, 7.8%/9.3%, and 4.9%/5.9% for one-, five-, and ten-year-survival studied in 2005 to 2009 [3]. Due to the sad fact that lung cancer is one of the leading causes of mortality for humans, there have been numerous at-tempts to stop this trend [4]. Despite the well developing treatment modalities, the ratio of lung cancer mortality rate to the incidence (0.8) is more than double the average mortal-ity/incidence ratio (0.3) among the population ＜65 years [5]. The incidence of lung cancer between the ≥65 years and ＜65 years old patients differs in 14%.

The Korean statistics are similar to the worldwide trends [6,7]. Furthermore, special circumstances were observed in the case of Korean patients: The profiles of EML4-ALK fu-sion gene variants of non-small-cell lung carcinoma (NSCLC)